CoChat

KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK–ERK pathway in pancreatic cancer

Open access
Yang, Kege, Li, Yaqing, Lian, Guoda, Lin, Haoming, Shang, Changzhen, Zeng, Linjuan, Chen, Shaojie, Li, Jiajia, Huang, Chumei, Huang, Kaihong, Chen, Yinting · 2018 · International Journal of Cancer
Cited by 88

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Oncogenic KRAS plays a crucial role in pancreatic ductal adenocarcinoma (PDAC) development and progression. However, the mechanism has not been clearly elucidated. RKIP is a tumor repressor, and loss of RKIP has been shown in PDAC. Here, we found that KRAS expression was inversely correlated with RKIP expression in PDAC fresh tissue regardless of the KRAS mutant status. The negative correlation between KRAS and RKIP was further confirmed in our PDAC tissue microarray. KRAS overexpression and RKIP downregulation were associated with poor clinical outcomes. Knockdown or overexpression of KRAS in PDAC cell lines robustly increased or decreased, respectively, RKIP protein and mRNA levels. Furthermore, the MAPK–ERK pathway was involved in the regulation of RKIP. KRAS‐regulated RKIP expression, which in turn affected the expression of pivotal epithelial–mesenchymal transition (EMT) and apoptosis factors. The biological function of the KRAS–RKIP axis was demonstrated in human pancreatic cancer cells in vitro and in vivo. KRAS knockdown increased RKIP expression and inhibited metastasis and chemoresistance. Moreover, the feature of metastasis and chemoresistance was rescued in the KRAS‐knockdown cells through the inhibition of RKIP by RNA interference. In conclusion, our studies demonstrate how KRAS inhibits the tumor suppressor RKIP, thus offering novel justification for targeting RKIP as a strategy to overcome KRAS‐induced tumor metastasis and chemoresistance in PDAC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.31248

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 88

Metadata

Authors
Yang, K., Li, Y., Lian, G., Lin, H., Shang, C., Zeng, L., Chen, S., Li, J., Huang, C., Huang, K., & Chen, Y.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2018-01-21
Volume
142
Issue
11
Pages
2323-2334
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2808140821
Cited by
88
References
8
FWCI
3.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK–ERK pathway in pancreatic cancer. https://app.cochat.ai/papers/10.1002/ijc.31248
The paper
Yang, K., Li, Y., Lian, G., Lin, H., Shang, C., Zeng, L., Chen, S., Li, J., Huang, C., Huang, K., & Chen, Y. (2018). KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK–ERK pathway in pancreatic cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.31248

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.